{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:28:40Z","timestamp":1787383720029,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972931"],"award-info":[{"award-number":["81972931"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173400"],"award-info":[{"award-number":["82173400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaut.2022.102929","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:23:31Z","timestamp":1666898611000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Genetic and pharmacological targeting of GSDMD ameliorates systemic inflammation in macrophage activation syndrome"],"prefix":"10.1016","volume":"133","author":[{"given":"Shunli","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingxian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7221-5084","authenticated-orcid":false,"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102929_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semarthrit.2020.12.007","article-title":"Understanding of cytokines and targeted therapy in macrophage activation syndrome","volume":"51","author":"Tang","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102929_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jaut.2022.102929_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102929_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jaut.2022.102929_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102929_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2022.102929_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/24725625.2020.1818961","article-title":"Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still's disease with a previous successful tocilizumab treatment","volume":"5","author":"Naniwa","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.jaut.2022.102929_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00296-019-04446-x","article-title":"Adult-onset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review","volume":"40","author":"Goda","year":"2020","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2022.102929_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2169\/internalmedicine.3727-19","article-title":"Elderly-onset still's disease complicated by macrophage activation syndrome: a case report and review of the literature","volume":"59","author":"Suda","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.jaut.2022.102929_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102929_bib11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102929_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102929_bib13","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2022.102929_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114585","article-title":"Targeting the gasdermin D as a strategy for ischemic stroke therapy","volume":"188","author":"Wang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jaut.2022.102929_bib15","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","article-title":"Gasdermin D in pyroptosis","volume":"11","author":"Burdette","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jaut.2022.102929_bib16","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1084\/jem.20190545","article-title":"Gasdermins and their role in immunity and inflammation","volume":"216","author":"Orning","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2022.102929_bib17","article-title":"Attenuation of rheumatoid arthritis through the inhibition of tumor necrosis factor-induced caspase 3\/gasdermin E-mediated pyroptosis","author":"Zhai","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2022.102929_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcsm.12662","article-title":"Amelioration of diabetes-induced inflammation mediated pyroptosis, sarcopenia, and adverse muscle remodelling by bone morphogenetic protein-7","volume":"12","author":"Aluganti Narasimhulu","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jaut.2022.102929_bib19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tcb.2021.03.004","article-title":"Punching holes in cellular membranes: biology and evolution of gasdermins","volume":"31","author":"De Schutter","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jaut.2022.102929_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2022.102929_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/IJN.S114477","article-title":"CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies","volume":"12","author":"Hanagata","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jaut.2022.102929_bib22","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?","volume":"44","author":"Ramanan","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102929_bib23","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","article-title":"Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102929_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2022.102929_bib25","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102929_bib26","first-page":"11","article-title":"Detection and prediction of macrophage activation syndrome in still's disease","author":"Javaux","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2022.102929_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac247","article-title":"Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease","author":"Ruscitti","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102929_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181caf100","article-title":"Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients","volume":"89","author":"Hot","year":"2010","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jaut.2022.102929_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102929_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061164","article-title":"The pathogenic role of interferons in the hyperinflammatory response on adult-onset still's disease and macrophage activation syndrome: paving the way towards new therapeutic targets","volume":"10","author":"Di Cola","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2022.102929_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41573-021-00154-z","article-title":"Channelling inflammation: gasdermins in physiology and disease","volume":"20","author":"Liu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2022.102929_bib32","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2022.102929_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108401","article-title":"Disulfiram inhibits IL-1beta secretion and inflammatory cells recruitment in Aspergillus fumigatus keratitis","volume":"102","author":"Yan","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.jaut.2022.102929_bib34","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/bph.14503","article-title":"Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jaut.2022.102929_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao5213","article-title":"Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes","volume":"363","author":"Akilesh","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaut.2022.102929_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12974-021-02357-y","article-title":"Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness","volume":"19","author":"Yates","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jaut.2022.102929_bib37","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3389\/fimmu.2019.03054","article-title":"TLR7 agonism accelerates disease and causes a fatal myeloproliferative disorder in NZM 2410 lupus mice","volume":"10","author":"Wirth","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:33:00Z","timestamp":1760257980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S0896841122001378"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102929","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and pharmacological targeting of GSDMD ameliorates systemic inflammation in macrophage activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}